FDA 2025 Cancer Drug Approvals: targeted therapy dominates
Artículo
Acceso abierto
Artículo
DOAJ
This commentary discusses the FDA’s drug approvals in 2025, with a particular focus on cancer therapies and the role of companion diagnostics (CDx). Cancer has emerged as the leading therapeutic area, accounting for 35...
LCC LCC:Internal medicineIdioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access